



m.m

0300 #4

Patent Application  
Attorney Docket No. PC11088ATMC

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 on this 23rd day of January 2002.

By

*Kelley D. Surprenant*  
(Signature of person mailing)  
Kelley D. Surprenant

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: David B. MacLean :

APPLICATION NO.: 09/995,130

: Examiner: To be assigned

FILING DATE: November 27, 2001

: Group Art Unit: To be assigned

TITLE: THERAPY FOR ANDROPAUSE USING  
ESTROGEN AGONISTS / ANTAGONISTS  
AND TESTOSTERONE

Hon. Commissioner for Patents  
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820, which lists the references, cited by the applicant(s), copies of which are enclosed.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Date:

*1/23/2002*

Respectfully submitted,

*Todd M. Crissey*

Todd M. Crissey  
Attorney for Applicant(s)  
Reg. No. 37,807

Pfizer Inc.  
Patent Department, MS 4159  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-4331